Hospital Ruber Internacional
- Address
- lock Available on a paid plan
Neurological Disorders – Epilepsy Research
Hospital Ruber Internacional’s neurology team is advancing the treatment of epilepsy and related encephalopathies through studies that assess safety and seizure‑reduction potential of emerging medicines.
- Adult focal (partial onset) epilepsy
- Refractory focal onset epilepsy
- Dravet syndrome and Lennox‑Gastaut syndrome
- Developmental and epileptic encephalopathies (DEE)
- Epilepsy associated with tuberous sclerosis complex
- KCNT1‑related developmental encephalopathy
The goal is to improve seizure control and quality of life for patients with rare and treatment‑resistant seizure disorders.
Oncology – Melanoma Immunotherapy
In the oncology unit, investigators are evaluating a biosimilar to Opdivo for patients with advanced melanoma, focusing on comparable efficacy and safety.
- Previously untreated unresectable melanoma
- Metastatic stage III/IV melanoma
- First‑line immunotherapy with nivolumab biosimilar
These trials aim to broaden access to effective immunotherapy options while maintaining clinical outcomes.
Oncology – Prostate Cancer Hormone Therapy
The department conducts research on prostate cancer to determine the optimal duration of androgen deprivation therapy combined with salvage radiotherapy after surgical recurrence.
- Recurrent prostate cancer post‑prostatectomy
- Short‑term versus long‑term ADT
- Salvage radiotherapy integration
Findings are expected to refine treatment protocols and improve long‑term disease‑free survival.
Neurodegenerative – Early Parkinson’s Disease
Studies at the site explore disease‑modifying strategies for Early Parkinson’s Disease, measuring impact on functional scores such as the MDS‑UPDRS.
- Early-stage Parkinson’s patients
- Movement Disorder Society Unified Parkinson’s Disease Rating Scale outcomes
- Time to first worsening event
The research seeks to delay progression and maintain daily living abilities for individuals newly diagnosed with Parkinson’s.
Rare Genetic & Congenital Disorders
A dedicated program investigates therapies for congenital, hereditary and neonatal neurological conditions, targeting specific genetic mutations that drive severe seizure phenotypes.
- KCNT1‑related developmental and epileptic encephalopathy
- Other rare developmental encephalopathies
- Genetically driven seizure disorders
By focusing on precision medicine, the trials aim to deliver targeted treatments that address the underlying genetic causes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1Biohaven Therapeutics Ltd.2active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Biohaven Therapeutics Ltd.3trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Ruber Internacional
lock Showing 1 of 32 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A DOSE-BLINDED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF UCB0599 IN STUDY PARTICIPANTS WITH PARKINSON’S DISEASE | UCB Biopharma | Phase II | Not Recruiting | Dec 2022 | Mar 2025 |
IMP list
lock Showing 1 of 28 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azetukalner | 3 | Unknown | 2019-05-28 | 2024-02-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.